Björn Dahlbäck

Q: What Schools Are Affiliated With Björn Dahlbäck

Björn Dahlbäck is affiliated with the following schools: Stockholm University, Uppsala University, Charing Cross and Westminster Medical School, Lund University, Linköping University

Björn Dahlbäck's AcademicInfluence.com Rankings

Björn Dahlbäck

Philosophy

#3195

World Rank

#5227

Historical Rank

Logic

#1006

World Rank

#1622

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Björn Dahlbäck's Degrees

Doctorate Medicine Uppsala University

Why Is Björn Dahlbäck Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Björn Dahlbäck is a Swedish physician, medical researcher, and professor of clinical chemistry, specializing in hematology and the molecular mechanisms of blood coagulation. He determined that activated protein C resistance is the most common inherited risk factor of venous thrombosis.

(See a Problem?)

Björn Dahlbäck's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. (1993) (2084)
Resistance to activated protein C as a basis for venous thrombosis. (1994) (1214)
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M (2011) (515)
Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. (1994) (486)
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis (2001) (452)
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis (1994) (447)
Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. (1994) (389)
High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. (1981) (360)
Protein S and C4b-Binding Protein: Components Involved in the Regulation of the Protein C Anticoagulant System (1991) (359)
Inactivation of human coagulation factor V by activated protein C. (1983) (341)
Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. (1994) (339)
Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. (1995) (337)
Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. (1995) (328)
Inherited Thrombophilia*: Part 2 (1996) (308)
Thrombotic risk during pregnancy: a population study. (1999) (304)
A Novel Human Apolipoprotein (apoM)* (1999) (299)
Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. (1983) (297)
Advances in understanding pathogenic mechanisms of thrombophilic disorders. (2008) (295)
Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. (1986) (291)
The anticoagulant protein C pathway (2005) (285)
Gas6 and protein S (2006) (278)
The 20210 A Allele of the Prothrombin Gene Is a Common Risk Factor among Swedish Outpatients with Verified Deep Venous Thrombosis (1997) (274)
The protein C anticoagulant system: inherited defects as basis for venous thrombosis. (1995) (272)
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. (2006) (261)
Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. (1995) (254)
HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation (2015) (247)
Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. (1995) (246)
Complete high‐density lipoproteins in nanoparticle corona (2009) (243)
Thrombin-catalyzed activation of human coagulation factor V. (1982) (237)
Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure–Function Relationships and Molecular Recognition (2005) (235)
Sedimentation and sulfate reduction under a mussel culture (1981) (233)
Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae (2001) (229)
Changes in the plasma levels of vitamin K‐dependent proteins C and S and of C4b‐binding protein during pregnancy and oral contraception (1988) (225)
Activated Protein C Resistance (FV:Q506) and Pregnancy (1999) (219)
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein (2002) (218)
Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases (1998) (211)
New Molecular Insights into the Genetics of Thrombophilia. Resistance to Activated Protein C Caused by Arg506 to Gin Mutation in Factor V as a Pathogenic Risk Factor for Venous Thrombosis (1995) (201)
Visualization of human C4b-binding protein and its complexes with vitamin K-dependent protein S and complement protein C4b. (1983) (200)
Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases (2005) (197)
Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? (2004) (193)
Thrombophilia as a multigenic disease. (1999) (193)
Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. (1985) (187)
Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. (1986) (184)
Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. (1994) (182)
Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. (1983) (175)
Coagulation factor V and thrombophilia: Background and mechanisms (2007) (172)
Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. (1995) (172)
Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice* (2008) (168)
Protein C, Protein S and c4b-Binding Protein in Severe lnfection and Septic Shock (1991) (163)
CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. (2003) (159)
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. (2008) (157)
Structural Requirements for the Complement Regulatory Activities of C4BP* (2001) (155)
C4b-binding Protein and Factor H Compensate for the Loss of Membrane-bound Complement Inhibitors to Protect Apoptotic Cells against Excessive Complement Attack* (2007) (148)
A highly variable region in members of the streptococcal M protein family binds the human complement regulator C4BP. (1996) (143)
Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival (2009) (140)
Novel subunit in C4b-binding protein required for protein S binding. (1988) (139)
Factor V Q506 Mutation (Activated Protein C Resistance) Associated with Reduced Intrapartum Blood Loss – a Possible Evolutionary Selection Mechanism (1998) (139)
Thromboembolic Disease – Critical Evaluation of Laboratory Investigation (1992) (138)
A Cluster of Positively Charged Amino Acids in the C4BP α-Chain Is Crucial for C4b Binding and Factor I Cofactor Function* (1999) (136)
The nanoparticle protein corona formed in human blood or human blood fractions (2017) (133)
Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethanolamine. (1992) (130)
Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. (2004) (128)
Analysis of Gas6 in Human Platelets and Plasma (2005) (126)
Multifunctional Specificity of the Protein C/Activated Protein C Gla Domain* (2006) (121)
beta-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. (1987) (118)
Human coagluation factor V purification and thrombin-catalyzed activation. (1980) (116)
Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. (1999) (115)
Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. (1995) (113)
Functional characterization of recombinant FV Hong Kong and FV Cambridge. (2002) (113)
Isolation and characterization of human apolipoprotein M-containing lipoproteins Published, JLR Papers in Press, May 8, 2006. (2006) (112)
The tale of protein S and C4b-binding protein, a story of affection (2007) (112)
Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. (1997) (111)
Primary structure of bovine vitamin K-dependent protein S. (1986) (110)
Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. (1990) (110)
Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. (1997) (109)
Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes (2012) (108)
Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S (1994) (107)
High-Density Lipoprotein–Associated Apolipoprotein M Limits Endothelial Inflammation by Delivering Sphingosine-1-Phosphate to the Sphingosine-1-Phosphate Receptor 1 (2017) (106)
Clarification of the Risk for Venous Thrombosis Associated with Hereditary Protein S Deficiency by Investigation of a Large Kindred with a Characterized Gene Defect (1998) (102)
Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. (1994) (101)
An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma Published, JLR Papers in Press, May 25, 2007. (2007) (100)
The C4b-binding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells* (2004) (100)
Progress in the understanding of the protein C anticoagulant pathway (2004) (99)
Structural changes in apolipoproteins bound to nanoparticles. (2011) (98)
Resistance to Activated Protein C Caused by the Factor V R506Q Mutation ls a Common Risk Factor for Venous Thrombosis (1997) (98)
C1‐TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration (2005) (97)
Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. (2011) (97)
Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood (2010) (97)
Human C4b-Binding Protein Has Overlapping, But Not Identical, Binding Sites for C4b and Streptococcal M Proteins1 (2000) (96)
Fibrillin immunoreactive fibers constitute a unique network in the human dermis: immunohistochemical comparison of the distributions of fibrillin, vitronectin, amyloid P component, and orcein stainable structures in normal skin and elastosis. (1990) (96)
Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. (2013) (95)
The hydrophobicity of bacteria — An important factor in their initial adhesion at the air-water inteface (2004) (95)
Independent association of serum amyloid P component, protein S, and complement C4b with complement C4b-binding protein and subsequent association of the complex with membranes. (1990) (94)
Protein S binding in relation to the subunit composition of human C4b‐binding protein (1989) (93)
Binding of anticoagulant vitamin K-dependent protein S to platelet-derived microparticles. (1992) (92)
Elevated Levels of Prothrombin Activation Fragment 1+2 in Plasma from Patients with Heterozygous Arg506 to Gin Mutation in the Factor V Gene (APC-Resistance) and/or Inherited Protein S Deficiency (1996) (91)
Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. (1997) (90)
Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes (2010) (88)
Vitamin K-Dependent Protein S Localizing Complement Regulator C4b-Binding Protein to the Surface of Apoptotic Cells1 (2002) (85)
Myocardial infarction associated with homozygous resistance to activated protein C (1994) (84)
Multicenter Evaluation of a Kit for Activated Protein C Resistance on Various Coagulation Instruments Using Plasmas from Healthy Individuals (1994) (83)
Binding of bovine coagulation factor Xa to platelets. (1978) (82)
Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site‐directed mutagenesis (2001) (81)
Molecular recognition in the protein C anticoagulant pathway (2003) (81)
Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. (2002) (80)
The amino-terminal module of the C4b-binding protein alpha-chain is crucial for C4b binding and factor I-cofactor function. (1997) (79)
Structural investigation of the A domains of human blood coagulation factor V by molecular modeling (1998) (79)
Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus (2011) (78)
Erythrocyte-Derived Microparticles Supporting Activated Protein C-Mediated Regulation of Blood Coagulation (2014) (78)
Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. (2008) (77)
Inhibition of Alzheimer β-Peptide Fibril Formation by Serum Amyloid P Component (*) (1995) (77)
Immunohistochemical demonstration of age-related deposition of vitronectin (S-protein of complement) and terminal complement complex on dermal elastic fibers. (1989) (76)
Evaluation of Original and Modified APC-Resistance Tests in Unselected Outpatients with Clinically Suspected Thrombosis and in Healthy Controls (1997) (76)
Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. (2006) (76)
Cloning of cDNA coding for the beta chain of human complement component C4b-binding protein: sequence homology with the alpha chain. (1990) (75)
A Common 4G Allele in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene as a Risk Factor for Pulmonary Embolism and Arterial Thrombosis in Hereditary Protein S Deficiency (1998) (75)
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries (1996) (74)
Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism (1995) (74)
Bordetella pertussis binds to human C4b‐binding protein (C4BP) at a site similar to that used by the natural ligand C4b (2001) (73)
Size-dependent effects of nanoparticles on enzymes in the blood coagulation cascade. (2014) (73)
Blood coagulation. (2000) (73)
Serum Amyloid P Component Binding to C4b-binding Protein (*) (1995) (73)
The C-terminal Region of the Factor V B-domain Is Crucial for the Anticoagulant Activity of Factor V* (1998) (73)
Interaction between vitamin K-dependent protein S and the complement protein, C4b-binding protein. A link between coagulation and the complement system. (1984) (73)
Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. (1986) (72)
Assembly of protein S and C4b-binding protein on membranes. (1990) (72)
Importance of Protein S and Phospholipid for Activated Protein C-mediated Cleavages in Factor Va* (2003) (72)
Novel type of very high affinity calcium-binding sites in beta-hydroxyasparagine-containing epidermal growth factor-like domains in vitamin K-dependent protein S. (1990) (71)
Functions of human complement inhibitor C4b-binding protein in relation to its structure. (2004) (71)
Polystyrene nanoparticles affecting blood coagulation. (2012) (71)
Characterization of apoM in normal and genetically modified mice Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.M300451-JLR200 (2004) (70)
A Novel Interaction Between Type IV Pili of Neisseria gonorrhoeae and the Human Complement Regulator C4b-Binding Protein1 (2001) (68)
Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-binding protein. (2002) (66)
The Signal Peptide Anchors Apolipoprotein M in Plasma Lipoproteins and Prevents Rapid Clearance of Apolipoprotein M from Plasma* (2008) (66)
High affinity interaction between C4b-binding protein and vitamin K-dependent protein S in the presence of calcium. Suggestion of a third component in blood regulating the interaction. (1990) (66)
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. (1996) (65)
Apolipoprotein M predicts pre‐β‐HDL formation: studies in type 2 diabetic and nondiabetic subjects (2009) (65)
Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis (2008) (64)
Localization of vitronectin (S-protein of complement) in normal human skin. (1986) (64)
Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis (2011) (64)
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. (1997) (63)
Anionic Phospholipids Lose Their Procoagulant Properties When Incorporated into High Density Lipoproteins* (2009) (63)
Ligand Recognition and Homophilic Interactions in Tyro3 (2004) (63)
Protein structural requirements and properties of membrane binding by gamma-carboxyglutamic acid-containing plasma proteins and peptides. (1989) (63)
Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. (1999) (62)
Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. (1990) (62)
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. (1999) (62)
The discovery of activated protein C resistance (2003) (62)
Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M Published, JLR Papers in Press, May 24, 2007. (2007) (62)
High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. (1996) (61)
Tensin3 Is a Negative Regulator of Cell Migration and All Four Tensin Family Members Are Downregulated in Human Kidney Cancer (2009) (61)
Cleavage requirements for activation of factor V by factor Xa. (1997) (61)
Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. (2009) (61)
The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. (2014) (61)
C4b-binding protein, a regulatory component of the classical pathway of complement, is an acute-phase protein and is elevated in systemic lupus erythematosus. (1990) (61)
Staphylococcus aureus alpha-toxin attack on human platelets promotes assembly of the prothrombinase complex. (1990) (60)
Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex. (1983) (59)
Resistance to activated protein C, the FV : Q506 allele, and venous thrombosis (1996) (58)
Blood coagulation (2000) (57)
The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis (1997) (57)
Structural investigation of C4b‐binding protein by molecular modeling: Localization of putative binding sites (1998) (57)
HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium (2017) (57)
The SHBG‐like region of protein S is crucial for factor V‐dependent APC‐cofactor function (1998) (56)
Structural and Energetic Characteristics of the Heparin-binding Site in Antithrombotic Protein C* (2001) (55)
Carriership of Factor V Leiden and evolutionary selection advantage. (2008) (55)
Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma (2009) (54)
Are we ready for factor V Leiden screening? (1996) (54)
The Ran binding protein RanBPM interacts with Axl and Sky receptor tyrosine kinases. (2005) (53)
The Amino-terminal Module of the C4b-binding Protein β-Chain Contains the Protein S-binding Site* (1996) (52)
Localization of thrombin cleavage sites in the amino-terminal region of bovine protein S. (1986) (52)
A New Direct, Fast and Quantitative Enzyme-linked Ligandsorbent Assay for Measurement of Free Protein S Antigen (1998) (52)
Thrombin-mediated Proteolysis of Factor V Resulting in Gradual B-domain Release and Exposure of the Factor Xa-binding Site* 210 (2002) (51)
Proposed structural models of the prothrombinase (FXa–FVa) complex (2006) (51)
Vitamin K–Dependent Protein S: Beyond the Protein C Pathway (2017) (51)
Improved Hemoglobin Status and Reduced Menstrual Blood Loss among Female Carriers of Factor V Leiden – An Evolutionary Advantage? (2001) (50)
A Shift in ApoM/S1P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM/S1P Complex (2017) (50)
Homozygous APC-resistance Combined with Inherited Type I Protein S Deficiency in a Young Boy with Severe Thrombotic Disease (1995) (50)
Pro‐ and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders (2016) (50)
Apolipoprotein M – a novel player in high-density lipoprotein metabolism and atherosclerosis (2006) (50)
Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. (2004) (49)
Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype. (2002) (49)
Apolipoprotein M associates to lipoproteins through its retained signal peptide (2008) (49)
C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae. (2001) (48)
Inhibitory effect of activated protein C on activation of prothrombin by platelet-bound factor Xa. (2005) (48)
Vitamin K-Dependent Protein S Localizing Complement Regulator C4b-Binding Protein to the Surface of Apoptotic Cells (2002) (48)
Ultrastructure of C4b-binding protein fragments formed by limited proteolysis using chymotrypsin. (1984) (47)
Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. (2003) (47)
Sphingosine 1‐phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in baboons (2016) (47)
Interaction between serum amyloid P component and C4b-binding protein associated with inhibition of factor I-mediated C4b degradation. (1994) (47)
Amino Acid Residues in Thrombin-sensitive Region and First Epidermal Growth Factor Domain of Vitamin K-dependent Protein S Determining Specificity of the Activated Protein C Cofactor Function* (1998) (47)
The Gas6-Axl Protein Interaction Mediates Endothelial Uptake of Platelet Microparticles* (2016) (46)
A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: From biostructural pathology to specie (1997) (46)
Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex (2000) (45)
Secondary Substrate-binding Exosite in the Serine Protease Domain of Activated Protein C Important for Cleavage at Arg-506 but Not at Arg-306 in Factor Va* (2001) (45)
Defining the Factor Xa-binding Site on Factor Va by Site-directed Glycosylation* (2002) (45)
Quantification of sphingosine 1-phosphate by validated LC-MS/MS method revealing strong correlation with apolipoprotein M in plasma but not in serum due to platelet activation during blood coagulation (2015) (45)
Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation (2004) (45)
Activated protein C resistance in patients with peripheral vascular disease. (1998) (44)
Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. (2000) (44)
Female Gender and Resistance to Activated Protein C (FV:Q506) as Potential Risk Factors for Thrombosis after Elective Hip Arthroplasty (1997) (43)
Opposing Effects of Apolipoprotein M on Catabolism of Apolipoprotein B–Containing Lipoproteins and Atherosclerosis (2010) (42)
Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. (1994) (42)
Plasma concentrations of C4b‐binding protein and vitamin K‐dependent protein S in term and preterm infants: low levels of protein S‐C4b‐binding protein complexes (1988) (42)
Factor V and protein S as cofactors to activated protein C. (1997) (41)
Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms. (1999) (41)
Activated protein C resistance – in the absence of factor V Leiden – and pregnancy (2006) (41)
The Role of Thrombin Exosites I and II in the Activation of Human Coagulation Factor V* (2007) (41)
Effects of Factor Xa and Protein S on the Individual Activated Protein C-mediated Cleavages of Coagulation Factor Va* (2006) (41)
Anti‐factor V auto‐antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding (2003) (41)
Positively charged amino acids at the interface between alpha-chain CCP1 and CCP2 of C4BP are required for regulation of the classical C3-convertase. (2000) (40)
Genetic and Phenotypic Variability between Families with Hereditary Protein S Deficiency (2002) (40)
Both G-type domains of protein S are required for the high-affinity interaction with C4b-binding protein. (1999) (40)
A Region of Vitamin K-dependent Protein S That Binds to C4b Binding Protein (C4BP) Identified Using Bacteriophage Peptide Display Libraries* (1997) (40)
Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. (2000) (40)
Large deletions of the PROS1 gene in a large fraction of mutation-negative patients with protein S deficiency (2005) (40)
Human genes for the alpha and beta chains of complement C4b-binding protein are closely linked in a head-to-tail arrangement. (1990) (39)
Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity. (1995) (39)
The gene encoding vitamin K-dependent anticoagulant protein S is expressed in multiple rabbit organs as demonstrated by northern blotting, in situ hybridization, and immunohistochemistry. (1995) (39)
Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma. (2017) (39)
Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue. (2011) (39)
Effects of Prothrombin on the Individual Activated Protein C-mediated Cleavages of Coagulation Factor Va* (2008) (39)
Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. (1998) (38)
Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S (2017) (38)
High affinity binding of human vitamin K-dependent protein S to a truncated recombinant beta-chain of C4b-binding protein expressed in Escherichia coli. (1993) (38)
Vitamin K-dependent protein S in Leydig cells of human testis. (1994) (37)
ApoM: gene regulation and effects on HDL metabolism (2009) (37)
Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system. (1997) (37)
SHBG region of the anticoagulant cofactor protein S: Secondary structure prediction, circular dichroism spectroscopy, and analysis of naturally occurring mutations (1997) (37)
Mutations in α-Chain of C4BP That Selectively Affect Its Factor I Cofactor Function* (2003) (37)
Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. (2010) (37)
The Second Laminin G-type Domain of Protein S Is Indispensable for Expression of Full Cofactor Activity in Activated Protein C-catalysed Inactivation of Factor Va and Factor VIIIa (2000) (36)
Congenital and acquired activated protein C resistance. (2003) (36)
Factor V Leiden in pregnancies complicated by placental abruption (2003) (36)
Structural stability and heat‐induced conformational change of two complement inhibitors: C4b‐binding protein and factor H (2004) (36)
Calcium binding of bovine protein S. Effect of thrombin cleavage and removal of the gamma-carboxyglutamic acid-containing region. (1986) (36)
Molecular cloning, expression and functional characterization of rabbit anticoagulant vitamin-K-dependent protein S. (1993) (36)
The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles (2012) (34)
Individual risk assessment of thrombosis in pregnancy (2002) (34)
Protein S secretion differences of missense mutants account for phenotypic heterogeneity. (2000) (33)
TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain. (2014) (33)
Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. (2010) (33)
An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA (2010) (33)
Microbial Investigations of Surface Microlayers, Water Column, Ice and Sediment in the Arctic Ocean (1982) (33)
The activation of prothrombin by platelet-bound factor Xa. (1980) (32)
Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. (2003) (32)
Implications of cerebrovascular ATP-binding cassette transporter G1 (ABCG1) and apolipoprotein M in cholesterol transport at the blood-brain barrier. (2017) (32)
Coagulation and inflammation—close allies in health and disease (2011) (32)
Involvement of Lys 62[217] and Lys 63[218] of Human Anticoagulant Protein C in Heparin Stimulation of Inhibition by the Protein C Inhibitor (1999) (32)
Bacterial activity at the air/water interface (1983) (32)
Activated protein C resistance as a basis for venous thrombosis. (1996) (32)
Protein S and factor V in regulation of coagulation on platelet microparticles by activated protein C. (2014) (32)
Characterization of recombinant epidermal growth factor (EGF)-like modules from vitamin-K-dependent protein S expressed in Spodoptera cells--the cofactor activity depends on the N-terminal EGF module in human protein S. (1998) (32)
Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation? (2009) (32)
Three‐dimensional model of the SHBG‐like region of anticoagulant protein S: New structure–function insights (2001) (32)
Structural Requirements of Anticoagulant Protein S for Its Binding to the Complement Regulator C4b-binding Protein* (2002) (31)
Inhibition of platelet prothrombinase activity by a lupus anticoagulant. (1983) (31)
Molecular cloning of rat C4b binding protein alpha- and beta-chains: structural and functional relationships among human, bovine, rabbit, mouse, and rat proteins. (1997) (31)
The binding of protein S and the protein S–C4BP complex to neutrophils is apoptosis dependent (2003) (31)
Probing the activation of protein C by the thrombin‐thrombomodulin complex using structural analysis, site‐directed mutagenesis, and computer modeling (1999) (31)
The multiple faces of the partial thromboplastin time APTT (2004) (30)
Molecular Models for the two Discoidin Domains of Human Blood Coagulation Factor V (1998) (30)
Localization of a Hydrophobic Binding Site for Anticoagulant Protein S on the β-Chain of Complement Regulator C4b-binding Protein* (2001) (30)
The First Laminin G-Type Domain in the SHBG-Like Region of Protein S Contains Residues Essential for Activation of the Receptor Tyrosine Kinase Sky (2000) (30)
Interactions between surface proteins of Streptococcus pyogenes and coagulation factors modulate clotting of human plasma (2003) (30)
Bleeding Complications Associated with Low Molecular Weight Heparin Prophylaxis during Pregnancy (2000) (29)
Biocompatibility of mannan nanogel--safe interaction with plasma proteins. (2012) (29)
Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. (2009) (29)
Topological Studies of the Amino Terminal Modules of Vitamin K-dependent Protein S Using Monoclonal Antibody Epitope Mapping and Molecular Modeling (1998) (29)
Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. (2003) (29)
Inhibition of Microarterial Thrombosis by Activated Protein C in a Rabbit Model (1994) (29)
Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia. (2010) (29)
Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized. (2003) (28)
Diagnosing protein S deficiency: analytical considerations. (2003) (28)
Analytical Considerations for Free Protein S Assays in Protein S Deficiency (2001) (28)
Structural prediction and analysis of endothelial cell protein C/activated protein C receptor. (1999) (28)
Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10. (1997) (28)
Platelet Factor 4 Impairs the Anticoagulant Activity of Activated Protein C* (2009) (28)
The protein S-binding site localized to the central core of C4b-binding protein. (1987) (27)
Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure (2020) (27)
C4b-binding protein: a forgotten factor in thrombosis and hemostasis. (2011) (26)
Tissue vitronectin in normal adult human dermis is non-covalently bound to elastic tissue. (1991) (26)
Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women (2003) (26)
Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993) (1994) (26)
Isolation of human tyrosinase from cultured melanoma cells. (1989) (25)
Resistance to activated protein C due to a factor V gene mutation The most common inherited risk factor of thrombosis. (1996) (25)
Factor V‐short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors (2017) (25)
Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits. (1995) (25)
Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. (2010) (25)
Plasma concentrations of apolipoproteins A-I, B and M in patients with abdominal aortic aneurysms. (2010) (25)
The human C4b-binding protein beta-chain gene. (1993) (24)
The complement regulator C4b-binding protein analyzed by molecular modeling, bioinformatics and computer-aided experimental design. (1999) (24)
Enhancement of Human Protein C Function by Site-directed Mutagenesis of the γ-Carboxyglutamic Acid Domain* (1998) (24)
Immunohistochemical studies on vitronectin in elastic tissue disorders, cutaneous amyloidosis, lichen ruber planus and porphyria. (1988) (24)
Vitronectin in mouse skin: immunohistochemical demonstration of its association with cutaneous amyloid. (1993) (23)
Familial hypercholesterolaemia: cholesterol efflux and coronary disease (2016) (23)
The C4b-binding protein-protein S interaction is hydrophobic in nature. (1998) (22)
Activated protein C resistance: from phenotype to genotype and clinical practice. (1995) (22)
Inhibition of complement components C3 and C4 by cadralazine and its active metabolite (2004) (22)
Use of Selective Factor V Leiden Screening in Pregnancy to Identify Candidates for Anticoagulants (2002) (22)
Mapping of the Factor Xa Binding Site on Factor Va by Site-directed Mutagenesis* (2008) (22)
Human C 4 b-Binding Protein Has Overlapping , But Not Identical , Binding Sites for C 4 b and Streptococcal M Proteins 1 (2000) (21)
Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. (1995) (21)
Heparin influence on the complex of serum amyloid P component and complement C4b-binding protein. (1991) (21)
Co‐segregation of the PROS1 locus and protein S deficiency in families having no detectable mutations in PROS1 (2004) (21)
Interspecies Loop Grafting in the Protease Domain of Human Protein C Yielding Enhanced Catalytic and Anticoagulant Activity (1999) (21)
Molecular genetics of venous thromboembolism. (1995) (20)
Activated protein C resistance caused by a common factor V mutation has a single origin. (1997) (20)
Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis. (1995) (20)
High‐density lipoprotein from end‐stage renal disease patients exhibits superior cardioprotection and increase in sphingosine‐1‐phosphate (2018) (19)
Rabbit Plasma, unlike Its Human Counterpart, Contains no Complex between Protein S and C4b-Binding Protein (1994) (19)
Apolipoprotein M: Progress in understanding its regulation and metabolic functions (2006) (19)
Cleavage Requirements of Factor V in Tissue-factor Induced Thrombin Generation (1998) (19)
The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels (2015) (19)
Bovine coagulation factor V visualized with electron microscopy. Ultrastructure of the isolated activated forms and of the activation fragments. (1986) (19)
Tensin2 reduces intracellular phosphatidylinositol 3,4,5-trisphosphate levels at the plasma membrane. (2010) (19)
Genetic risk factors for venous thromboembolism (2020) (18)
Actuated protein C resistance: From phenotype to genotype and clinical practice (1995) (18)
Vitronectin shows complement-independent binding to isolated keratin filament aggregates. (1989) (18)
Expression and characterization of a recombinant C4b-binding protein lacking the beta-chain. (1995) (18)
Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus (1996) (18)
Identification of the MMRN1 Binding Region within the C2 Domain of Human Factor V* (2004) (18)
Enhanced Rate of Cleavage at Arg-306 and Arg-506 in Coagulation Factor Va by Gla Domain-mutated Human-activated Protein C* (2004) (18)
Bovine C4b binding protein. Molecular cloning of the alpha- and beta-chains provides structural background for lack of complex formation with protein S. (1994) (17)
Individual domains of Tensin2 exhibit distinct subcellular localisations and migratory effects. (2010) (17)
Expression of completely γ‐carboxylated and β‐hydroxylated recombinant human vitamin‐K‐dependent protein S with full biological activity (1990) (17)
The association between apolipoprotein M and insulin resistance varies with country of birth. (2014) (17)
Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis. (1996) (17)
Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin. (2000) (17)
Protein S Thr103Asn Mutation Associated with Type II Deficiency Reproduced In Vitro and Functionally Characterised (2000) (17)
C4b-binding protein (C4BP) beta-chain Short Consensus Repeat-2 specifically contributes to the interaction of C4BP with protein S. (1999) (17)
Human C4BP binds to the hypervariable N-terminal region of many members in the streptococcal M protein family. (1997) (16)
In Vitro Characterisation of Two Naturally Occurring Mutations in the Thrombin-sensitive Region of Anticoagulant Protein S (1999) (16)
Small and large PROS1 deletions but no other types of rearrangements detected in patients with protein S deficiency (2012) (16)
Thrombophilia: the discovery of activated protein C resistance. (1995) (16)
Two new candidate mutations in type IIA von Willebrand's disease (ARG834→GLY, GLY846→ARG) and one polymorphism (TYR821→CYS) in the A2 region of the von Willebrand factor (1993) (16)
Plasma apoM and S1P levels are inversely associated with mortality in African Americans with type 2 diabetes mellitus (2019) (16)
Molecular Model for the C-type Lectin Domain of Human Thrombomodulin (1998) (15)
Dependence on Vitamin K-dependent Protein S for Eukaryotic Cell Secretion of the β-Chain of C4b-binding Protein* (2010) (15)
cDNA structure of rabbit C4b-binding protein alpha-chain. Preserved sequence motive in complement regulatory protein modules which bind C4b. (1995) (15)
Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans. (2010) (15)
Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. (2010) (15)
Assignment of gene for coagulation factor V to chromosome 1 in man and to chromosome 13 in rat (1988) (15)
Dr. Dahlbäck’s Response to the Letter by Dr. Keeling - Factor V: Q506 and a Negative APC-Resistance Test - Modified APC-Resistance Test Offers Increased Sensitivity and Specificity for the FV: Q506 Allele (1995) (15)
Screening the molecular surface of human anticoagulant protein C: A search for interaction sites (2001) (15)
Inhibition of Thrombin Formation by Active Site Mutated (S360A) Activated Protein C* (2010) (15)
Altered inactivation pathway of factor Va by activated protein C in the presence of heparin. (2004) (15)
Multicentre Evaluation of IL Test™ Free PS: A Fully Automated Assay to Quantify Free Protein S (2002) (15)
Early days of APC resistance and FV Leiden (2008) (14)
Interaction between complement component C4b-binding protein and the vitamin K-dependent protein S. A link between blood coagulation and the complement system. (1985) (14)
Inherited resistance to activated protein C, a major basis of venous thrombosis, is caused by deficient anticoagulant cofactor function of factor V. (1995) (14)
Plasma concentrations of apolipoproteins A-I, B, and M in patients with critical limb ischemia. (2010) (14)
Novel APC‐cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S (2010) (14)
The gene encoding vitamin K-dependent anticoagulant protein C is expressed in human male reproductive tissues. (1995) (14)
The Plasma Lipocalins α1-Acid Glycoprotein, Apolipoprotein D, Apolipoprotein M and Complement Protein C8γ (2013) (13)
Ligand Recognition and Homophilic Interactions in Tyro3 STRUCTURAL INSIGHTS INTO THE Axl/Tyro3 RECEPTOR TYROSINE KINASE FAMILY* (2004) (13)
Ultrastructure of human coagulation factor V. (1985) (13)
Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. (2011) (13)
Genes for C4b-binding protein α- and β-chains (C4BPA andC4BPB) are located on chromosome 1, band 1q32, in humans and on chromosome 13 in rats (1990) (13)
An Arg545→ Cys545 substitution mutation of the von Willebrand factor in type IIB von Willebrand's disease (1991) (13)
Activated protein C cofactor function of protein S : a critical role for Asp 95 in the EGF 1-like domain (2010) (13)
Identification of Surface Epitopes of Human Coagulation Factor Va That Are Important for Interaction with Activated Protein C and Heparin* (2008) (13)
A Shift in ApoM / S 1 P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM / S 1 P Complex (2017) (12)
State-of-the-Art Review: Activated Protein C Resistance: Clinical Implications (1997) (12)
Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S (2003) (12)
Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism. (2014) (12)
Factor V Q506 (Resistance to Activated Protein C) and Prognosis after Acute Coronary Syndrome (1999) (12)
Immunohistochemical demonstration of vitronectin in association with elastin and amyloid deposits in human kidney (2004) (12)
Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome (2007) (11)
Urinary apolipoprotein M as a biomarker of acute kidney injury in children undergoing heart surgery. (2016) (11)
Protein unfolding allows use of commercial antibodies in an apolipoprotein M sandwich ELISA[S] (2015) (11)
Epidemiology of Familial Aggregation of Venous Thromboembolism (2016) (11)
Functional properties of recombinant factor V mutated in a potential calcium-binding site. (2004) (11)
Mouse recombinant protein C variants with enhanced membrane affinity and hyper‐anticoagulant activity in mouse plasma (2009) (11)
The Challenge to Find New Sustainable Antifouling Approaches for Shipping (2010) (11)
Amino acid residues in the laminin G domains of protein S involved in tissue factor pathway inhibitor interaction (2015) (10)
Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis. (1997) (10)
New functional test for the TFPIα cofactor activity of Protein S working in synergy with FV‐Short (2019) (10)
The role of phospholipid transfer protein in lipoprotein‐mediated neutralization of the procoagulant effect of anionic liposomes (2010) (10)
Plasma concentrations of Gas 6 and sAxl correlate with disease activity in systemic lupus erythematosus (2011) (10)
Resistance to activated protein C caused by a Factor V gene mutation (1995) (10)
Low plasma concentrations of apolipoprotein M are associated with disease activity and endothelial dysfunction in systemic lupus erythematosus (2019) (10)
The importance of the protein C system in the pathogenesis of venous thrombosis (2005) (9)
Inhibition of human vitamin-K-dependent protein-S-cofactor activity by a monoclonal antibody specific for a Ca2+-dependent epitope. (1987) (9)
Mouse ApoM displays an unprecedented seven-stranded lipocalin fold: folding decoy or alternative native fold? (2010) (9)
Identification of polymorphisms in Apolipoprotein M gene and their relationship with risk of recurrent venous thromboembolism (2016) (9)
Role of CCP2 of the C4b-binding protein beta-chain in protein S binding evaluated by mutagenesis and monoclonal antibodies. (2003) (9)
Apolipoprotein M: structure and function (2008) (8)
HDL stimulates apoM secretion. (2010) (8)
Gas6‐Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor‐progressive advantages (2017) (8)
APC resistance: What have we learned since 1993? / APC-Resistenz: Was haben wir seit 1993 hinzugelernt? (2004) (7)
Gas 6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma (2009) (7)
Umbilical cord plasma levels of growth‐arrest specific protein 6 in intrauterine growth restriction (2010) (6)
ATP level of a starving surface-bound and free-living marine Vibrio sp. (1984) (6)
Plasma levels of apolipoprotein M in normal and complicated pregnancy (2010) (6)
Classic Thrombophilias and Thrombotic Risk Among Middle‐Aged and Older Adults: A Population‐Based Cohort Study (2022) (6)
The preAR2 region (1458–1492) in factor V‐Short is crucial for the synergistic TFPIα‐cofactor activity with protein S and the assembly of a trimolecular factor Xa‐inhibitory complex comprising FV‐Short, protein S, and TFPIα (2021) (6)
Expression of completely gamma-carboxylated and beta-hydroxylated recombinant human vitamin-K-dependent protein S with full biological activity. (1990) (6)
A new model for coagulation factor V suggesting a unique mechanism of activation. (1988) (6)
Binding of C 4 b-binding protein : A molecular mechanism of serum resistance of Neisseria gonorrhoeae (2001) (5)
PROTEIN C, PROTEIN S AND THE FIBRINOLYTIC SYSTEM IN PATIENTS WITH A HISTORY OF THROMBOSIS (1987) (5)
Factor V Leiden and the genetics of myocardial infarction: we need to look elsewhere (2002) (5)
Binding of C4b-Binding Protein to Porin (2001) (4)
Surface of Apoptotic Cells Complement Regulator C 4 b-Binding Protein Vitamin K-Dependent Protein S Localizing (2002) (4)
Synergistic Cofactor Function of Factor V and Protein S to Activated Protein C in the Inactivation of the Factor Villa – Factor IXa Complex (1997) (4)
Lean ApoM−/− Mice with Hyperactive Brown Adipose Tissue (2018) (4)
HEMATOPOIESIS Cleavage of Factor V at Arg 506 by Activated Protein C and the Expression of Anticoagulant Activity of Factor (1999) (4)
Protein C, a Regulator of Prothrombin Activation (1982) (4)
Protein unfolding allow use of commercial antibodies in an apolipoprotein M sandwich ELISA (2015) (3)
1 The Gas 6-Axl interaction mediates endothelial uptake of platelet microparticles (3)
A hydrophobic patch (PLVIVG; 1481–1486) in the B‐domain of factor V‐short is crucial for its synergistic TFPIα‐cofactor activity with protein S and for the formation of the FXa‐inhibitory complex comprising FV‐short, TFPIα, and protein S (2022) (3)
595: The miR21/10b ratio as a prognostic marker in metastasis-free clear cell renal cell carcinoma patients (2014) (3)
disorders Advances in understanding pathogenic mechanisms of thrombophilic (2008) (3)
Low FV beneficial in FVFVIII deficiency? (2019) (3)
Successful hunt for quantitative trait locus in thrombophilia. (2003) (3)
MAJOR RISK FACTOR FOR VENOUS THROMBOSIS (1997) (3)
Advances in Understanding Mechanisms of Thrombophilic Disorders (2020) (3)
Pleiotropic anticoagulant functions of protein S, consequences for the clinical laboratory. Communication from the SSC of the ISTH (2021) (3)
Chapter 9B Inhibitors: protein C (1986) (3)
Anticoagulant factor V and thrombosis risk (2004) (3)
Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human activated protein C in rats. (2007) (3)
The miR Ratio As a Prognostic Marker in Clear Cell Renal Cell Carcinoma (2015) (3)
The D2194G mutation is responsible for increased levels of FV1 in carriers of the factor V R2 haplotype (2010) (3)
Rapid Intracellular Degradation of a Truncated Mutant Protein S (Q522X) (2002) (3)
Evaluation of Expression Level of Apolipoprotein M as a Diagnostic Marker for Primary Venous Thromboembolism (2018) (3)
European Arctic Initiatives Compendium (2014) (2)
Apolipoprotein M Improves Survival in Congestive Heart Failure via Enhanced Akt Signaling (2016) (2)
ISOLATION AND CHARACTERIZATION OF cDNA CLONES FOR HUMAN FACTOR V (1987) (2)
Viability of a marine microbial biofilm (1982) (2)
Some Remarks on the Epidemiology of Thrombotic Disorders – Rebuttal to the Letter of Drs F. Rodeghiero and A. Tosetto (1993) (2)
European Arctic initiatives : capacities, gaps and future opportunities (2016) (2)
LOW PLASMA CONCENTRATIONS OF C4b-BINDING PROTEIN AND VITAMIN K-DEPENDENT PROTEIN S IN PRETERM INFANTS WITH DECREASED FORMATION OF PROTEIN S-C4b-BINDING PROTEIN COMPLEXES (1987) (2)
Bordetella pertussis binds to human C4BP (C4B-binding protein) at a site similar to that used by the natural ligand C4b (2000) (2)
Coagulation factor VA 2440 G causes east Texas bleeding disorder via TFPI alpha (2013) (2)
Symposium in memory of Professor Inga Marie Nilsson (2001) (2)
Molecular coagulation and thrombophilia. (2005) (2)
[A newly discovered blood coagulation disorder. Resistance to activated protein C as a cause of thrombosis]. (1994) (2)
Gas6 fueling tumor-mediated thrombosis. (2016) (2)
Treating hemophilia by targeting protein S? (2018) (2)
Human activated protein C variants in a rat model of arterial thrombosis (2008) (2)
Resistance to activated protein C, the FV: Q506 allele, and venous thrombosis (1998) (2)
Molecular basis of coagulation factor V deficiency caused by the R1698W inter-domain mutation (2013) (2)
Erratum: HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P to limit vascular inflammation (Science Signaling) (2015) (2)
Abstract: 614 ANTICOAGULANT PROPERTIES OF APOLIPOPROTEIN A-I AND PHOSPHOLIPID TRANSFER PROTEIN (2009) (1)
Binding of C4b-binding protein: A molecular mechanism of serum resistance of Neisseria gonorrhoeae (2001) (1)
Prothrombin Activation in the Presence of Platelets (1979) (1)
[APC resistance, oral contraceptives and thrombosis. Screening is justified for diagnosing high-risk cases]. (1997) (1)
Lipid metabolism: why is apoM an apolipoprotein? (2008) (1)
Relationship Between Plasma Apolipoprotein-M And High Density Lipoprotein Apoa Kinetics In Men (2009) (1)
Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels: modification by adiposity in nondiabetic subjects (2011) (1)
The molecular basis of type I/III protein S deficiency (1999) (1)
Correction: C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. (2020) (1)
Natural anticoagulant discovery, the gift that keeps on giving: finding FV-Short. (2023) (1)
[Vitronectin in normal human skin and in skin lesions]. (1991) (1)
Presence of vitamin K-dependent coagulation proteins in isolated triglyceride-rich lipoproteins of human plasma. (1997) (1)
[Resistance to activated protein C. A common genetic risk factor in venous thrombosis]. (1995) (1)
European Arctic Initiatives Compendium : Preparatory Action, Strategic Environmental Impact Assessment of development of the Arctic (2014) (1)
Resistance to Activated Protein C, the Arg506 to Gin Mutation in the Factor V Gene, and Venous Thrombosis (1995) (1)
Identification of the Multimerin Binding Region within the C2 Domain of Human Factor V Using Constructs Generated by Alanine-Scanning and Site-Directed Mutagenesis. (2004) (1)
Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH (2022) (1)
Subjects Index, Vol. 26, Supplement 4, 1996 (1996) (0)
静脈血栓塞栓症研究の既往と現在【JST・京大機械翻訳】 (2016) (0)
Downregulation of C1‐TEN expression in human cancer (2007) (0)
THU0260 Low plasma concentrations of apolipoprotein m correlate to disease activity and endothelial dysfunction in sle (2017) (0)
150 Low plasma concentrations of apolipoprotein m correlate to disease activity and endothelial dysfunction in sle (2017) (0)
Results Gas 6 is Present in Plasma but Undetectable in Human Platelets (2005) (0)
Molecular coagulation and thrombophilia (2019) (0)
Authors Index, Vol. 26, Supplement 4, 1996 (1996) (0)
Abstract LB-146: Investigation of Gas6/Axl signaling in clear cell renal cell carcinoma tumor cells and endothelial cells in presence of the first line treatment drug Sunitinib Malate (2014) (0)
G ENETIC LOSS OF G AS 6 INDUCES P LAQUE S TABILITY IN EXPERIMENTAL A THEROSCLEROSIS (2014) (0)
REGULATION OF BLOOD COAGULATION BY THE PROTEIN C PATHWAY (2007) (0)
activated protein C-catalyzed factor Va-inactivation Re-evaluation of the role of the protein S-C4b binding protein complex in (2013) (0)
Stable serum resistance of Neisseria gonorrhoeae is mediated by binding of C4B-binding protein to gonococcal porin (2000) (0)
Large deletions of the PROS 1 gene in a large fraction of mutation-negative patients with protein S deficiency (2018) (0)
ATP-binding cassette transporter G1 and apolipoprotein M are 'Novel players' in cholesterol transport at the blood-brain barrier. (2017) (0)
A cluster of positively charged amino acids at the interface between C4BP CCP1 and CCP2 is crucial for binding of C4b and streptococcal proteins (2000) (0)
Complement Regulator C 4 b-Binding Protein and the Human Neisseria gonorrhoeae A Novel Interaction Between Type IV Pili of Lindahl (2001) (0)
coagulant response to Escherichia coli Role of free protein S and C4b binding protein in regulating the (2011) (0)
Thrombotic risk associated with protein S (PS) gene mutation and an explanation for the familial coexistence of type I and type III PS-deficient phenotypes (1997) (0)
362 Characterization of recombinant vitamin K-dependent protein S (1988) (0)
Investigation of C4b-binding protein by molecular modeling (1998) (0)
[Control of oral anticoagulant therapy. The Quick method is one step back]. (1993) (0)
Gas6: an orchestrator of platelet-endothelial-leukocyte cell interactions during hemostasis and inflammation (2006) (0)
17 THE PLASMA CONCENTRATION OF HDL-ASSOCIATED APOM IS CONTROLLED BY THE ACTIVITY OF THE LDL-RECEPTOR (2011) (0)
Endothelial Biomedicine: Vitamin K–Dependent Anticoagulant Protein S (2007) (0)
Research in the field ofvenous thromboembolism: history, current perspectives and future directions (2016) (0)
endothelial cells, platelets and leukocytes GAS6 promotes inflammation by enhancing interactions between (2013) (0)
486 APOLIPOPROTEIN M (APOM) – A NOVEL BIOMARKER FOR ACUTE KIDNEY INJURY (2011) (0)
P233 ACTIVE PHOSPHOLIPID TRANSFER PROTEIN (PLTP) REDUCES PROTHROMBIN ACTIVATION AND ATTENUATES BLOOD COAGULATION (2010) (0)
Apolipoprotein M is decreased in type 2 diabetes and affects pre beta high density lipoprotein formation and cellular cholesterol efflux (2009) (0)
Abstract: P1149 RECOMBINANT APOLIPOPROTEIN M SECRETION STIMULATED BY HDL (2009) (0)
Targeting exosites of activated protein C as therapeutic possibility? (2014) (0)
[Use the entire "analysis package" when investigating patients with venous thrombosis! Don't forget the relatives...]. (2000) (0)
Structure of apolioprotein M in complex with Sphingosine 1-Phosphate (2011) (0)
Effect of apolipoprotein M on modulation of HDL in APOM transgenic and APOM deficient mice (2007) (0)
Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia (2011) (0)
Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis (1997) (0)
associated with thrombosis Functional characterization of factor V-Ile359Thr: a novel mutation (2013) (0)
Inherited resistance to activated protein C and venous thrombosis (1996) (0)
Growth arrest specific protein 6 (gas6) and its receptors expression and signalling in beta cells (2010) (0)
Crystal Structure of Mouse Apolipoprotein M (2010) (0)
IIB von W illebr and' s disease : mutations and clinical presentation in nine families Denmark, Germany and Sweden (1992) (0)
Crystal structure of human apoM in complex with myristic acid (2009) (0)
Protein GAS6 and its receptor Axl are expressed and operate in pancreatic beta cells (2009) (0)
PROTEIN S-C4BP COMPLEX STIMULATES ACTIVATED PROTEIN C-MEDIATED INACTIVATION AT R306 BUT INHIBITS INACTIVATION AT R506 IN FACTOR VA (2007) (0)
Abstract: P404 EXPRESSION OF APOLIPOPROTEIN M IN FETAL LIVER: IMPACT OF MATERNAL DIABETES (2009) (0)
Methodological considerations on the determination of the APC response in plasma (1995) (0)
The D 2194 G mutation is responsible for increased levels of FV 1 in carriers of the factor V R 2 haplotype (2018) (0)
The Mediterranean League Against Thromboembolic Diseases / Spanish Society of Thrombosis and Haemostasis (1994) (0)
Coagulation factor V Leiden not increased in pregnancies complicated by abruptio placentae (2003) (0)
Coagulation and inflammation—close allies in health and disease (2011) (0)
Genetic polymorphism in a region of the vWF pseudogene corresponding to exon 28 of the vWF gene (1992) (0)
Heparin Important for Interaction with Activated Human Coagulation Factor Va That Are Identification of Surface Epitopes of Enzyme Catalysis and Regulation : (2008) (0)
Localisation of the protein S binding site on the C4BP β-chain (2000) (0)
We-W35:1 Genetic mechanisms of thrombophilia (2006) (0)
phenotypic heterogeneity Protein S secretion differences of missense mutants account for (2013) (0)
The Tensin Family Of Putative Metastasis Suppressor Proteins Are Down-Regulated In Human Kidney Cancer (2008) (0)
APOLIPOPROTEIN M IS BOUND TO LIPOPROTEINS VIA ITS RETAINED SIGNAL PEPTIDE (2008) (0)
A method for detecting protein-s (1997) (0)
R2 haplotype Molecular basis of quantitative factor V deficiency associated with factor V (2013) (0)
[A test for APC resistance prior to prescription of oral contraceptives? Discussion about screening should be based on facts]. (1995) (0)
Interaction between C4B-binding protein and protein S is hydrophobic in nature (1998) (0)
Corrigendum to Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH [J Thromb Haemost. 2022 Jul;20(7):1735-1743]. (2023) (0)
- 1-Mouse apoM displays an unprecedented 7-stranded lipocalin fold-Folding decoy or alternative native fold ? (2011) (0)
Mice deficient in growth arrest specific gene 6 (Gas6) show increased hemorrhage in atherosclerosis, myocardial infarction and after LPS-footpad injection and exhibit increased VEGF induced capillary hyperpermeability (2003) (0)
Quality in Laboratory Hemostasis and Thrombosis (2010) (0)
Plasma Concentrations of Growth Arrest Specific Protein 6 and the Soluble Form of its Tyrosine Kinase Receptor Axl in Abdominal Aortic Aneurysms (2009) (0)
387 Fibrinolytic studies in patients with congenital protein C or protein S deficiency (1988) (0)
Title Page / Table of Contents, Vol. 26, Supplement 4, 1996 (1996) (0)
HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium (2017) (0)
Correction: C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. (2020) (0)

This paper list is powered by the following services:

Other Resources About Björn Dahlbäck

en.wikipedia.org

What Schools Are Affiliated With Björn Dahlbäck?

Björn Dahlbäck is affiliated with the following schools:

Björn Dahlbäck's Academic­Influence.com Rankings